Login
$REPL
$21.32 -$0.09 (0.42%) After hours

$REPL SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 Form 4: Slattery Joseph P, Director

Sold 5,200 shares ($113K)

10 Nov 2026 SCHEDULE 13G
09 Nov 2026 144
09 Nov 2026 SCHEDULE 13G/A
06 Nov 2026 FORM 10-Q/A
03 Nov 2026 Form 4: Dhingra Kapil, Director

Received 43,169 shares by exercise or conversion ($75.5K) · Sold 21,500 shares ($409K)

03 Nov 2026 144
02 Nov 2026 144
30 Oct 2026 144
28 Oct 2026 144
28 Oct 2026 10-Q
28 Oct 2026 8-K: Results of Operations and Financial Condition

TUDRIQEV first delivered to patients for advanced melanoma on October 6th

16 Sep 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF REPLIMUNE GROUP, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware)

24 Aug 2026 Form 4: Astley-Sparke Philip, Director

Gave 50,000 shares as a gift

19 Aug 2026 Form 4: Hill Emily Luisa, Chief Financial Officer

Sold 9,256 shares ($132K)

14 Aug 2026 S-3ASR
14 Aug 2026 10-Q
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 8-K: Results of Operations and Financial Condition

TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support